Case 15 - Diabetes Insipidus

Q1. Diagnosis: Diabetes Insipidus (Central/Cranial type) - and Why

Q2. Other Conditions in Which Polyuria Occurs

1. Diabetes Mellitus - osmotic diuresis from glucosuria (but urine has high specific gravity and contains glucose - opposite of DI)
2. Psychogenic (Primary) Polydipsia - excessive voluntary water intake; urine dilute but responsive to water restriction
3. Nephrogenic Diabetes Insipidus - renal tubular resistance to ADH (same presentation as central DI but does not respond to exogenous ADH/desmopressin)
4. Chronic Renal Failure - loss of concentrating ability (isosthenuria, SG ~1.010)
5. Hypercalcaemia - calcium interferes with ADH action on collecting ducts
6. Hypokalaemia - impairs renal concentrating mechanisms
7. Primary Hyperaldosteronism (Conn's syndrome) - osmotic effects of sodium retention
8. Diuretic use - pharmacological (loop diuretics, thiazides)
9. Osmotic diuresis - high-solute loads (mannitol, IV contrast, high-protein feeds)
10. Recovery phase of acute tubular necrosis (ATN)

Q3. Comment on Blood Sugar Level in This Patient

• Despite the misleading name "diabetes" (which means "to pass through/siphon"), Diabetes Insipidus has nothing to do with blood glucose.
• The word "insipidus" = tasteless/colourless urine (as opposed to "mellitus" = honey-sweet urine in Diabetes Mellitus).
• The defect in DI is in ADH/vasopressin, not insulin. Pancreatic function and glucose metabolism are completely unaffected.
• Urine specifically shows no sugar, confirming normoglycaemia.
• Fasting blood glucose, HbA1c, and glucose tolerance test would all be normal.

Case 16 - Graves' Disease (Hyperthyroidism)

• Diffuse goitre (sometimes with thyroid bruit)
• Exophthalmos (proptosis)
• Lid retraction - described in Miller's Anesthesia as a hallmark of Graves' disease with "lid retraction, wide stare, and exophthalmos"

How to Relieve Muscular Spasm

Understanding the Mechanism First

1. Immediate/Non-Pharmacological Relief

Stretching (Most Effective)

• Gently stretch and hold the affected muscle in the opposite direction of the spasm
• Example: for a calf cramp, pull the toes upward (dorsiflexion) while keeping the knee straight
• This activates the Golgi tendon organ (GTO) reflex, which inhibits the motor neuron causing the spasm

Heat Therapy

• Apply a warm compress or heating pad to the spasming muscle
• Heat increases blood flow, relaxes muscle fibres, and reduces the local ischemia that drives the spasm
• Best for: chronic, recurring spasms, back muscle spasms

Cold/Ice Pack

• Useful in the first 24-48 hours if the spasm follows acute injury/inflammation
• Numbs the area and reduces inflammatory mediators
• Apply for 15-20 minutes at a time

Massage

• Manual pressure and kneading of the muscle breaks the spasm-pain cycle
• Improves local circulation and promotes relaxant metabolite clearance
• Myofascial release techniques are especially useful for chronic spasm

Rest and Position

• Avoid positions that shorten the spasming muscle
• For lumbar (back) spasm: lie flat or in a supported position; avoid pillows under the knee (per Miller's Review of Orthopaedics)

Hydration and Electrolyte Replacement

• Dehydration and electrolyte imbalances (low Na⁺, K⁺, Ca²⁺, Mg²⁺) are common triggers
• Drink adequate water; consider oral rehydration salts or a banana (potassium) for exercise-induced cramps
• Hyponatremia, hypocalcaemia, and hypomagnesaemia are well-documented causes of cramp (Bradley and Daroff's Neurology)

2. Pharmacological Treatment

3. Physical Therapy Approaches (for Chronic/Recurrent Spasm)

• Trigger point therapy - direct pressure on hyperirritable muscle knots
• TENS (Transcutaneous Electrical Nerve Stimulation) - electrical current disrupts pain-spasm cycle
• Dry needling / Acupuncture - deactivates trigger points
• Ultrasound therapy - deep heat promotes tissue relaxation
• Progressive strengthening exercises - prevents recurrence by improving muscular endurance

4. Treat the Underlying Cause

Quick Summary

For an acute spasm: STRETCH → HEAT → MASSAGE → NSAID/relaxant if needed. For chronic spasm: address the underlying cause + physiotherapy + appropriate muscle relaxant. For spasm from electrolyte deficiency: rehydrate and replenish electrolytes first.

Case 17 - Diabetic Ketoacidosis (DKA)

Q.1. Diagnosis?

• Blood glucose = 350 mg/dL (severely elevated, normal is 70-110 mg/dL)
• Breath is sweet and aromatic = acetone/ketone breath (fruity odour from exhaled acetone)
• Ketone bodies found in urine (ketonuria)
• Coma (from acidosis + hyperosmolality)
• BP 200/110 mmHg (stress-induced hypertension)

• Kussmaul breathing (deep, rapid) to blow off CO₂
• Sweet/aromatic/fruity breath from exhaled acetone
• Coma from acidosis + severe hyperosmolality + dehydration

Q.2. Aromatic Breath - Cause?

Case 18 - Post-Thyroidectomy Hypocalcaemia / Tetany

Q.1. Cause of Muscular Fasciculations?

• Fall in serum calcium (PTH normally raises calcium by acting on bone, kidney, and gut)
• Low Ca²⁺ increases neuronal excitability → spontaneous firing → muscle fasciculations, cramps, and tetany

• Chvostek's sign (tapping facial nerve → facial twitch)
• Trousseau's sign (BP cuff inflation → carpal spasm)
• Fasciculations, carpopedal spasm, laryngospasm in severe cases

Q.2. How to Relieve Muscular Spasm in This Case?

Case 19 - Pregnancy (Amenorrhoea)

Q.1. Cause of Amenorrhoea?

Q.2. Simple Test to Confirm Amenorrhoea (i.e., Confirm Pregnancy)?

• hCG is produced by the trophoblast cells of the implanted embryo from as early as 6-8 days post-fertilisation
• It doubles every ~48 hours in early pregnancy
• Urine strip test is simple, cheap, rapid (~5 minutes), highly sensitive (>99%), and can be done at home or in a clinic
• Serum beta-hCG is even more sensitive and can detect pregnancy earlier (before a missed period)

Case 20 - Haemophilia (Classic)

Q.1. Probable Cause of Bleeding from Multiple Sites?

• Male child (X-linked recessive - affects males)
• Bleeding from nose (epistaxis), mouth, urinary tract (haematuria), alimentary tract (GI bleed), and skin after trivial injury
• Swelling of joints after bleeding (haemarthrosis - pathognomonic of haemophilia)
• Persistent bleeding despite it not being profuse
• Family history of similar bleeding in male relatives (X-linked pattern)

Q.2. Physiological Basis for This Disorder?

• Factor VIII is a co-factor in the intrinsic coagulation pathway
• It forms a complex with Factor IXa (the "tenase complex") to activate Factor X
• Factor X activation is a key step in generating thrombin and forming a stable fibrin clot

• Factor VIII is absent or severely reduced
• The intrinsic pathway is defective → insufficient thrombin generation → clot formed is weak and unstable
• Primary platelet plug forms (hence bleeding time is NORMAL, petechiae are absent) but the secondary fibrin clot fails to stabilise
• Result: persistent, prolonged bleeding especially into deep tissues, joints (haemarthrosis), and muscles

Q.1. Most Likely Diagnosis (Case 21)?

• Red, sore, smooth tongue (glossitis - atrophic glossitis from B12/folate deficiency)
• Pins and needles (peripheral neuropathy - subacute combined degeneration of cord from B12 deficiency)
• Periodic diarrhoea with mucus (GI mucosal atrophy)
• Fatigue, breathlessness, anorexia, pallor (anaemia symptoms)
• 55-year-old female (typical age for pernicious anaemia)

Q.2. Physiological Basis for Treatment?

• B12 is needed for DNA synthesis (especially for rapidly dividing cells like RBC precursors)
• B12 is also essential for myelin synthesis - deficiency causes the neurological features (pins and needles, subacute combined degeneration)
• Folic acid supplementation helps the anaemia but does NOT correct the neurological damage - B12 must be given

Physiological Basis of Treatment of Haemophilia

Step 1: Understanding the Normal Physiology (What is Missing?)

Contact activation
       ↓
XII → XIIa → XI → XIa → IX → IXa
                              ↓
                    IXa + VIIIa + Ca²⁺ + Phospholipid
                    (INTRINSIC TENASE COMPLEX)
                              ↓
                           Factor X → Xa
                              ↓
                    Xa + Va + Ca²⁺ + Phospholipid
                    (PROTHROMBINASE COMPLEX)
                              ↓
               Prothrombin (II) → THROMBIN (IIa)
                              ↓
               Fibrinogen → FIBRIN (stable clot)

Step 2: The Physiological Defect

• Both affect only males (who have one X chromosome)
• Females are carriers (heterozygous) and rarely symptomatic
• Clinically identical - only distinguished by specific factor assays

• Platelet plug forms normally (so bleeding time is NORMAL, no petechiae)
• But the fibrin clot is weak and unstable → persistent deep bleeding into joints (haemarthrosis), muscles, soft tissues
• PTT is prolonged, PT is normal

Step 3: Physiological Basis of Each Treatment

A. Factor Replacement Therapy (CORNERSTONE)

• Prophylactic treatment: regular infusions to maintain factor levels >1% and prevent spontaneous bleeds
• On-demand: infusion at time of bleeding episode
• Factor VIII half-life = 8-12 hours, so frequent dosing is needed

B. Emicizumab (Hemlibra) - Novel Non-Factor Therapy

• Given subcutaneously (not intravenously like factor concentrates)
• Particularly useful in patients who develop inhibitors (antibodies) against Factor VIII (~15% of severe haemophilia A patients after treatment)
• A landmark advance as it bypasses the need for the deficient factor entirely

C. DDAVP (Desmopressin) - for Mild Haemophilia A

• Since vWF stabilizes and carries Factor VIII in plasma, this release acutely raises Factor VIII levels 2-4 fold
• Effective only in mild haemophilia A where residual Factor VIII is present
• NOT useful in severe haemophilia A or haemophilia B

D. Recombinant Factor VIIa (for Inhibitor Patients)

E. Gene Therapy (Emerging/Approved)

• For Haemophilia B: gene therapy is already approved (one-time infusion)
• For Haemophilia A: in late-phase clinical trials
• This is the closest to a cure - the body makes its own factor continuously

Summary Table

PROBLEM 1 - Dyspnoeic Index (DI)

Given:

• Maximum Voluntary Ventilation (MVV) = 120 L/min
• Resting Respiratory Rate = 12/min
• Tidal Volume = 500 mL = 0.5 L

Step 1: Calculate Minute Volume (MV)

Minute Volume = Resting Respiratory Rate × Tidal Volume

Step 2: Calculate Dyspnoeic Index (DI)

DI = (MVV - MV) / MVV × 100

Definitions (Q.1 & Q.2)

BR = MVV - MV = 120 - 6 = 114 L/min

DI = (MVV - MV) / MVV × 100

Comment on the Values:

• A DI of 95% means 95% of the maximum breathing capacity is still in reserve at rest.
• The person is breathing at only 5% of their maximum capacity at rest - completely normal.
• DI < 70% would indicate dyspnoea (insufficient reserve).
• This individual is NOT dyspnoeic.

PROBLEM 2 - FEV₁ % (FEV₁/VC × 100)

Formula:

FEV₁% = (FEV₁ / VC) × 100

Calculations:

Q.1 - Which Subject Most Likely Has Airway Obstruction? And Why?

• Subject B has FEV₁% = 57.5%, which is well below the normal cut-off of ≥70-80%
• In obstructive lung disease (asthma, COPD), FEV₁ falls more than VC because narrowed airways trap air and resist expiratory airflow, so less air can be forced out in 1 second
• The hallmark of obstruction = low FEV₁/VC ratio

Q.2 - Define VC and FEV₁

PROBLEM 3 - Breathing Reserve and Dyspnoeic Index

Given:

• MVV = 120 L/min
• Minute Volume (MV) = 80 L/min

Calculations:

Comment on the Values:

• A DI of only 33.3% means the person is using 67% of their maximum ventilatory capacity just at rest
• The breathing reserve is drastically reduced (only 40 L/min vs normal >100 L/min)
• This person would be severely dyspnoeic - even minimal exertion would push them to their maximum ventilatory limit
• This pattern is seen in severe obstructive lung disease (COPD, severe asthma), restrictive disease, or neuromuscular weakness

Rule of thumb: When DI falls below 70%, the patient experiences dyspnoea. At 33.3%, this patient is in significant respiratory distress even at rest.

Recent Pulmonary Function Testing (PFT) Guidelines & Standards

The Landmark Documents (2019-2023)

1. Spirometry Standards (2019 ATS/ERS Update)

Test Performance Criteria

• Good start: Extrapolated volume (EV) <5% of FVC or <150 mL (whichever is greater)
• No cough in the first second affecting FEV₁
• Satisfactory end: either >6 seconds duration (adults) or volume plateau (<25 mL change for ≥1 second)
• No glottis closure (Valsalva), no leaks, no obstructed mouthpiece

• Difference between best two FEV₁ values: <150 mL (previously <200 mL)
• Difference between best two FVC values: <150 mL
• If FVC <1.0 L: criterion is <100 mL

• Grade A = ≥3 acceptable + repeatability met (most reliable)
• Grade F = no usable maneuvers

2. Interpretive Strategies (2022 ERS/ATS - The Major Update)

A. Z-Scores Replace % Predicted

Why Z-scores? Fixed % predicted cutoffs introduce age and sex bias - they over-diagnose obstruction in the elderly and under-diagnose it in the young. Z-scores describe how many standard deviations a value lies from the predicted mean for that individual's demographics.

B. Race-Neutral (GLI Global) Reference Equations

• Race-specific equations historically assigned lower predicted values to Black patients, potentially masking lung disease
• Race is a social construct, not a biological variable that should adjust lung function normals
• The ATS officially endorsed race-neutral reporting in a 2023 position statement

C. Updated Bronchodilator Responsiveness (BDR) Criteria

• FEV₁ increase ≥10% of predicted (not just 10% of baseline), OR
• FVC increase ≥10% of predicted
• Removes the absolute 200 mL threshold (which disadvantaged patients with small lungs)

• Salbutamol/Albuterol: 4 × 100 µg = total 400 µg via spacer, 30-second intervals
• Repeat spirometry after 10-15 minutes
• Ipratropium: 4 × 40 µg = total 160 µg, repeat after 30 minutes

D. Updated Interpretation Framework (3-Step Approach)

• Yes → Obstructive pattern
• No → Go to Step 2

• FVC low, FEV₁/FVC normal or high → Restrictive pattern (confirm with TLC)
• Both normal → Normal spirometry

3. Lung Volume Measurement Standards (2023 ERS/ATS Update)

• Linked spirometry now standardized alongside plethysmography
• New equipment quality control requirements for body plethysmographs and gas dilution systems
• Multiple Breath Washout (MBW) generalized beyond nitrogen washout - now includes SF₆ and other tracer gases
• New acceptability and grading system with example tracings
• GLI 2022 reference values recommended for TLC, FRC, and RV as well

4. DLCO (Diffusing Capacity) Standards

• Single-breath DLCO (DLCO-SB) is the recommended method
• Correct for haemoglobin concentration
• Normal: DLCO > LLN (using GLI reference equations)
• Reduced DLCO with normal spirometry → consider emphysema, pulmonary vascular disease, ILD

5. Special Populations - 2022 Updates

• Children: GLI equations apply from age 3; end-of-test criteria >3 seconds (not 6)
• Elderly: Z-scores prevent over-diagnosis of "obstruction" from normal age-related FEV₁/FVC decline
• Obese patients: Seated spirometry; note that obesity reduces FRC
• Neuromuscular disease: Consider supine spirometry - a >20% fall from seated to supine FVC suggests diaphragmatic weakness

6. Quality Control Updates (2019 Standard)

Key Takeaways

1. Use Z-scores and LLN, not fixed 70% or 80% cutoffs - this is the single most important change
2. Use race-neutral GLI 2022 equations for all patients regardless of ethnicity
3. Repeatability criterion tightened to 150 mL (from 200 mL)
4. BDR is now 10% of predicted (not 12% of baseline + 200 mL)
5. Grade spirometry A-F to communicate result reliability
6. Probabilistic interpretation - spirometry gives likelihood of disease, not a definitive diagnosis alone

⚠️ Note: The ATS issued a supplementary statement in 2023 specifically recommending against using race as a biological variable in PFT interpretation, citing concerns about health equity - aligning with the GLI 2022 race-neutral equations.